Tropomodulin 1 is essential for chemotherapy sensitivity and associated with better outcome in triple-negative breast cancer
High TMOD1 expression in TNBC patients is associated with better prognosis. Although TMOD1 expression promotes TNBC cell proliferation, migration, and invasion, TMOD1 enhances the sensitivity to Dox therapy both in vivo and in vitro, which might contribute to improve the prognosis for TNBC patients.
Authors
- Xiao Lin (ORCID: https://orcid.org/0000-0002-4857-7269)
- Yiting Xie (ORCID: https://orcid.org/0000-0002-8880-9474)
- Yijie Li (ORCID: https://orcid.org/0009-0004-3636-9624)
- Mengjia Shen (ORCID: https://orcid.org/0000-0003-1748-3726)
- Ting Luo (ORCID: https://orcid.org/0000-0002-2923-9344)
- Xinyi Long
- Shiyu Cao (ORCID: https://orcid.org/0000-0002-8714-2559)
- Feng Ye (ORCID: https://orcid.org/0000-0002-9159-7767)
- Fei Chen (ORCID: https://orcid.org/0000-0002-3077-5902)
- Lijuan Yin (ORCID: https://orcid.org/0000-0002-3269-0902)
- Xiaorong Zhong
Institutions
- Sichuan University (CN)
- West China Medical Center of Sichuan University (CN)
- West China Hospital of Sichuan University (CN)
- Health and Family Planning Commission of Sichuan Province (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1186/s12885-025-14961-9
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Chinese Society of Clinical Oncology
- Chengdu Science and Technology Bureau
- Natural Science Foundation of Sichuan Province